ESC 365 - Biomarkers for monitoring patients with cardiac amyloidosis during transthyretin-stabilizer therapy

ESC Professional Premium Access

Biomarkers for monitoring patients with cardiac amyloidosis during transthyretin-stabilizer therapy

Session: Cardiac amyloidosis, sarcoidosis, and inflammation

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Speaker: Doctor J. Vogel (Essen, DE)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor Julia Kirsten Vogel

University of Duisburg-Essen - West-German Heart and Vascular Center, Essen (Germany)

1 follower

8 more presentations in this session

Delays in diagnosis and treatment initiation of ATTR cardiac amyloidosis: a real-world data analysis

Speaker: Doctor J. Vogel (Essen, DE)

Transthyretin stabiliser therapy in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis

Speaker: Mr V. Ribeiro (Teresina, BR)

Prevalence of transthyretin amyloid cardiomyopathy in patients hospitalised for heart failure with preserved ejection fraction in an LATAM center.

Speaker: Mr S. Decotto (Buenos Aires, AR)

Relationship between changes in renal function after acute phase of tafamidis administration and left ventricular diastolic function at mid-term follow-up in transthyretin cardiac amyloidosis

Speaker: Ms A. Senda (Kobe, JP)

Prevalence of amyloidosis among patients with mild to severe aortic stenosis. Validation of screening parameters.

Speaker: Doctor F. Voss (Duesseldorf, DE)

Access the full session

Cardiac amyloidosis, sarcoidosis, and inflammation

Speakers: Doctor J. Vogel, Doctor J. Vogel, Mr V. Ribeiro, Mr S. Decotto, Ms A. Senda...

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources